基本信息
views: 6
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
He has extensive experience treating patients with blood cancers. He has a particular interest in chronic myeloid leukemia (CML) and myeloproliferative neoplasms, a group of blood cancers related to leukemia.
As a clinician-scientist trained in hematology/oncology as well as molecular biology I have been interested in the biology and therapy of leukemia and myeloproliferative neoplasms (MPNs) for more than 20 years. I have led an extramurally funded laboratory for 15 years and have assembled a team of researchers and technicians that provides an excellent training environment. Our technical expertise encompasses molecular and cellular biology, chemistry and chemical biology, murine leukemia models and ex vivo analysis of primary leukemia cells (we have established a substantial biorepository with >20,000 samples from >1,200 patients). We have made a number of contributions to our field of study that have influenced how leukemia and MPNs are diagnosed, treated and monitored. I have played an important role in multiple clinical studies in MPNs, including chronic myeloid leukemia (CML) that contributed to the establishment of tyrosine kinase inhibitor (TKI) - based therapies as the standard of care. Today our work continues, focusing on novel therapeutic targets in leukemia, novel drugs to overcome TKI resistance in CML and other MPNs, and to understand the role of bone marrow micro environment for leukemogenesis. Over the years I have trained and mentored a number of pre- and postdoctoral students and clinical fellows. Several of my trainees have secured faculty positions at major academic institutions in Europe or the US, and have attracted extramural funding to establish their own independent research groups. Having been involved in research for many years the success of my trainees has become a key measure of my own achievement. I profoundly enjoy the opportunity to get inspired by young investigators setting out to develop their research careers and I am determined to help them on their path to independence.
Research Interests
Papers共 669 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
GENOME RESEARCHno. 1 (2024): 94-105
Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan,Shinya Kimura,Michael W. Deininger,Jong-Won Kim,Dennis Dong Hwan Kim
Leukemiano. 2 (2024): 412-415
Jorge E. Cortes,Koji Sasaki, Dong-Wook Kim,Timothy P. Hughes, Gabriel Etienne,Michael J. Mauro,Andreas Hochhaus, Fabian Lang,Michael C. Heinrich,Massimo Breccia,Michael Deininger,Yeow Tee Goh,
LEUKEMIApp.1-12, (2024)
Bloodno. 23 (2023): 2797-2812
Meenu Kesarwani,Zachary Kincaid,Mohammad Azhar, Jacob Menke, Joshua Schwieterman,Sekhu Ansari, Angela Reaves,Michael E. Deininger,Ross Levine,H. Leighton Grimes,Mohammad Azam
Leukemiano. 8 (2023): 1686-1697
Fieke W. Hoff, Ying Huang, Rina Li Welkie,Ronan T. Swords,Elie Traer,Eytan M. Stein,Tara L. Lin,Prapti A. Patel,Robert H. Collins,Maria R. Baer,Vu H. Duong,William Blum,
BLOOD (2023): 4296
Nataly Cruz-Rodriguez,Dongqing Yan, Briana Bates,Daniela Uribe-Cano, Tony Pomicter,Michael Deininger
BLOOD (2023): 41
Helong Zhao, Kent Johnson,Anthony Pomicter, Briana Bates,Benjamin Bateman, Jonathan Ahmann, Jenna Bishop,Dongqing Yan,Greg Lee,Torsten Haferlach,Weiquan Zhu,Shannon Odelberg,
Clinical Lymphoma, Myeloma & Leukemia (2023): S287-S288
CLINICAL LYMPHOMA MYELOMA & LEUKEMIAno. S3 (2023): 204-205
Meenu Kesarwani,Zachary Kincaid,Mohammad Azhar, Jacob Menke, Joshua Schwieterman,Sekhu Ansari, Angela Reaves,Michael E Deininger,Ross Levine,H Leighton Grimes,Mohammad Azam
Leukemiano. 8 (2023): 1686-1697
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn